Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens - Wikidata - wikimedia - TriplyDB

Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens

Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens

http://www.wikidata.org/entity/Q27658173

about

Antibody promiscuity: Understanding the paradigm shift in antigen recognition Conserved structural elements in the V3 crown of HIV-1 gp120 Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1 Crystal Structure of the HIV-2 Neutralizing Fab Fragment 7C8 with High Specificity to the V3 Region of gp125 Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120 Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected Humans Thermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120 Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.Back to the future: covalent epitope-based HIV vaccine development.Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding.Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1 Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.Human immunodeficiency virus-1 gp120 V3 loop for anti-acquired immune deficiency syndrome drug discovery: computer-aided approaches to the problem solving.Basic research in HIV vaccinology is hampered by reductionist thinking.Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.Mimicking Protein-Protein Interactions through Peptide-Peptide Interactions: HIV-1 gp120 and CXCR4 HIV-1 Cross-reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Non-human Primate.Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.Quantitative assessment of masking of neutralization epitopes in HIV-1.Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

P2860

Q26801316-AA32B321-DD3B-47CD-A6DE-6C1EE3A1387C Q27663325-6033B8B5-777B-4F4C-A297-F1E46F4753E9 Q27666407-6BDBEE59-D82C-4DD5-84F1-2A0CF8ADD1E6 Q27667679-CC10977A-7A24-4B69-8FBA-733CBEA4CBA4 Q27667819-C0959FD8-1985-47BE-83A8-339179318F7D Q27676155-59EA73E6-EFA0-4659-9612-2D95F728EF90 Q27676728-EB0BBE5A-E2A1-4086-A9E9-A17682324F03 Q27677941-00B65FD8-2C0A-4394-AE52-F1EE0C9C08C4 Q27679123-C9AC4785-B7F7-4432-B1A8-54B9F20A3372 Q27679559-CD8EA04E-86E5-44DF-88E0-467D0E417449 Q28743129-53261421-2865-434A-82E8-749B54645289 Q28752503-80808AD6-332C-4B9B-A6E2-E71AFD870CDF Q30155145-0A569071-1E1D-466E-B053-6E417487726C Q30355260-39B969BE-A77E-4F17-9F43-E26F2684F969 Q30603475-FAD0616D-4FB7-4454-A3D6-53C7D966F5E9 Q30994182-142317C1-8D5D-499D-81DB-2440D7C49BF1 Q33759392-266167D6-F8B2-4EB9-BB9E-9F9CC575AE56 Q34034659-7353907C-45AD-44B9-905B-26E03FC0454B Q34100194-F08A0D10-2395-4F08-AC0E-ED0B23982989 Q34128200-D1FEF017-14C8-4924-A749-5752534FAAA3 Q34204047-EB45BFFB-C2E9-4FA9-8C1F-B4FBCAB919DB Q34533041-5E6D4960-394C-4672-957B-E3A28A742F6F Q34597300-AD61DA0A-B71C-4993-B267-919F00BBC983 Q34847834-D0C26F4B-B41F-46F3-96A6-4808BD371A0C Q34948847-ED3583A7-B7DC-45A1-A509-75F984F8EC02 Q35108505-7891827C-5A3B-4F61-8D5B-B943412D9170 Q35196671-79A9F52C-E7DA-4BD4-A8B8-B5D7521D7598 Q35909563-552F8DE2-3967-473A-B590-F12FD8AE35DC Q35913910-BFE6FBC0-6BFA-4110-94B9-292EFC002762 Q36213478-D6A068A5-823C-4FFF-A230-F280E0C7D708 Q36827348-EA884D68-2B32-473D-AEB8-727775C5DBB9 Q36920319-16FCE7EA-0BEC-415A-AE92-62F57538A082 Q38014473-27BF9713-B6EC-410B-B6F5-AA8559E9E7AA Q38025633-E59D8E72-EEBF-427C-9FF4-A5757ECC496E Q38968180-33FAA668-2759-4480-ABBC-2C744480E246 Q39034394-46E49837-5E08-41C1-BA47-172953FDCC34 Q40073016-8C5EEF36-763E-4AFF-BE93-2708F97CDAEE Q40092127-E0E4D31B-D74D-4635-9E7E-76CB071224BC Q41909663-649A17C3-5D3A-46DD-8891-7FB8E1A442D1 Q42204816-CEA9F026-E4EF-4AC2-BCE8-03F91ED8303E

P2860

Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens

http://www.wikidata.org/entity/Q27658173

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@ast

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@en

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@nl

type

label

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@ast

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@en

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@nl

prefLabel

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@ast

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@en

Structural Basis of the Cross- ...... Design of V3-Based Immunogens

@nl

P1433

Q27658173-CF6B0F27-63BB-4F9B-8143-44922B285582

P1476

Q27658173-C42C29BD-1C9C-4019-9B4C-244EEC93BAF4

P2093

Q27658173-4924686C-3F15-404D-9464-EE8DB887181D

Q27658173-4BEE1C59-C6A9-4A20-9492-AA1354E12186

Q27658173-A94B45B1-B525-4AE7-B858-73C1B42FEFA2

Q27658173-AA42903C-9DB0-4F26-BC26-425366DF9929

Q27658173-CE285B77-F910-44F5-AA37-B1E6EA2901D5

Q27658173-E790843B-19A0-4537-9894-2E4E50BCEF12

Q27658173-F5569EE4-F77C-4568-BCCB-270A84A1774E

P2860

Q27658173-000C16B7-EFB8-4E2D-AD22-ECB6958AECE2

Q27658173-0B5D5AC4-7E10-40FD-8C26-054D7E80D39B

Q27658173-0FF3ED05-2E30-422D-9CB7-70EB92282CC0

Q27658173-14E21338-6F83-49C8-82BB-F184A331A0F6

Q27658173-19CBBA52-31B1-473A-B7BC-3E4FE34F80B7

Q27658173-1AB8D619-B42A-4110-BC5C-6B810196919E

Q27658173-212E8E85-8BC2-42B5-9624-7262008253F4

Q27658173-2849E3AC-0255-4873-B0AB-C507CF0C0A90

Q27658173-3493CFD3-1295-4D1B-82A3-01024250FC20

Q27658173-3806E367-908E-4505-9EC0-E8AF510DB633

P304

Q27658173-B705D22A-BC0D-4669-8869-FE06346A9D83

P31

Q27658173-13FFA0FF-FAC4-4152-94F1-8B83ECD99534

P356

Q27658173-FBDF3CAA-3A09-4CFC-AA46-22B6536EF399

P433

Q27658173-5CF5813E-5EFA-4E29-9A2B-512EC04E3132

P478

Q27658173-24CF7F44-2D8A-4B25-B23A-B08C2AB9A1D0

P50

Q27658173-C3ACD3FA-3D93-4BFC-B1BF-6954A0F4A32F

Q27658173-E8C4124F-4546-4C38-9266-44D3828BB87F

P577

Q27658173-4EC7E701-0D15-4FA4-AD0B-15A3DA858E1F

P5875

Q27658173-023F0194-A1B9-430B-A216-1E62215E86F3

P698

Q27658173-6C77D2DD-5BF8-4407-8A57-AE1D40A5130F

P921

Q27658173-D760B623-47DB-4692-927B-360A8748467D

P932

Q27658173-CB97827F-89CA-412D-B245-9F06AAA1FD41

P356

J.STR.2009.09.012

P1433

P1476

Structural basis of the cross- ...... design of V3-based immunogens

@en

P2093

Constance Williams

http://www.w3.org/2001/XMLSchema#string

Huiguang Li

http://www.w3.org/2001/XMLSchema#string

Madhav Sukumaran

http://www.w3.org/2001/XMLSchema#string

Seung-Sup Kim

http://www.w3.org/2001/XMLSchema#string

Susan Zolla-Pazner

http://www.w3.org/2001/XMLSchema#string

Valicia Burke

http://www.w3.org/2001/XMLSchema#string

Xiao-Hong Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D

Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4

Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization

Structure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data set

Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells

Structure of a V3-containing HIV-1 gp120 core

P304

1538-1546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.STR.2009.09.012

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Xiang-Peng Kong

Miroslaw K Gorny

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38089464

http://www.w3.org/2001/XMLSchema#string

P698

19913488

http://www.w3.org/2001/XMLSchema#string

P921

structural biology

P932

3683248

http://www.w3.org/2001/XMLSchema#string